Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | peroxisome proliferator-activated receptor alpha | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Schistosoma japonicum | ko:K08701 nuclear receptor, subfamily 1, invertebrate, putative | Get druggable targets OG5_137778 | All targets in OG5_137778 |
Schistosoma mansoni | nuclear hormone receptor superfamily protein-related | Get druggable targets OG5_137778 | All targets in OG5_137778 |
Schistosoma japonicum | IPR008946,Nuclear receptor, ligand-binding,domain-containing | Get druggable targets OG5_137778 | All targets in OG5_137778 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | ecdysteroid receptor | peroxisome proliferator-activated receptor alpha | 468 aa | 397 aa | 25.4 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | DNA gyrase/topoisomerase IV, A subunit family protein | 0.0201 | 0.3777 | 0.5 |
Trypanosoma brucei | DNA topoisomerase II beta, putative | 0.018 | 0.321 | 1 |
Onchocerca volvulus | Putative DNA topoisomerase 2, mitochondrial | 0.0145 | 0.2229 | 0.5 |
Trypanosoma cruzi | DNA topoisomerase II, putative | 0.018 | 0.321 | 1 |
Brugia malayi | DNA topoisomerase II, alpha isozyme | 0.0201 | 0.3777 | 0.5 |
Echinococcus granulosus | DNA topoisomerase 2 alpha | 0.0201 | 0.3777 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0135 | 0.1925 | 0.4103 |
Plasmodium falciparum | DNA topoisomerase 2 | 0.0201 | 0.3777 | 1 |
Wolbachia endosymbiont of Brugia malayi | DNA gyrase, topoisomerase II, B subunit, GyrB | 0.0066 | 0 | 0.5 |
Chlamydia trachomatis | DNA gyrase subunit B | 0.0109 | 0.1203 | 1 |
Trichomonas vaginalis | DNA topoisomerase II, putative | 0.0201 | 0.3777 | 0.5 |
Echinococcus multilocularis | DNA topoisomerase 2 alpha | 0.0201 | 0.3777 | 0.5 |
Plasmodium vivax | DNA topoisomerase II, putative | 0.0201 | 0.3777 | 1 |
Giardia lamblia | DNA topoisomerase II | 0.0192 | 0.3528 | 0.5 |
Onchocerca volvulus | DNA topoisomerase 2 homolog | 0.0145 | 0.2229 | 0.5 |
Loa Loa (eye worm) | TOPoisomerase family member | 0.0201 | 0.3777 | 1 |
Entamoeba histolytica | DNA topoisomerase II, putative | 0.0201 | 0.3777 | 0.5 |
Trypanosoma brucei | DNA topoisomerase II alpha, putative | 0.018 | 0.321 | 1 |
Mycobacterium tuberculosis | DNA gyrase (subunit B) GyrB (DNA topoisomerase (ATP-hydrolysing)) (DNA topoisomerase II) (type II DNA topoisomerase) | 0.0066 | 0 | 0.5 |
Brugia malayi | Probable DNA topoisomerase II | 0.0201 | 0.3777 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0135 | 0.1925 | 0.4103 |
Treponema pallidum | DNA gyrase, subunit B (gyrB) | 0.0066 | 0 | 0.5 |
Toxoplasma gondii | DNA topoisomerase 2, putative | 0.0201 | 0.3777 | 1 |
Trypanosoma cruzi | DNA topoisomerase II, putative | 0.018 | 0.321 | 1 |
Leishmania major | DNA topoisomerase ii | 0.018 | 0.321 | 1 |
Mycobacterium ulcerans | DNA gyrase subunit B | 0.0066 | 0 | 0.5 |
Onchocerca volvulus | DNA topoisomerase 2 homolog | 0.0145 | 0.2229 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (binding) | uM | Effective concentration for human peroxisome proliferator-activated receptor delta | ChEMBL. | 15713415 |
EC50 (binding) | 0 uM | Effective concentration for human peroxisome proliferator-activated receptor delta | ChEMBL. | 15713415 |
EC50 (binding) | = 14 uM | Effective concentration for human peroxisome proliferator-activated receptor gamma | ChEMBL. | 15713415 |
EC50 (binding) | = 14 uM | Effective concentration for human peroxisome proliferator-activated receptor gamma | ChEMBL. | 15713415 |
EC50 (binding) | = 15 uM | Effective concentration for human peroxisome proliferator-activated receptor alpha | ChEMBL. | 15713415 |
EC50 (binding) | = 15 uM | Effective concentration for human peroxisome proliferator-activated receptor alpha | ChEMBL. | 15713415 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.